Related Experiment Videos

The effect of triamcinolone acetonide on the phagocytosis by human polymorphonuclear leukocytes

International Journal of Clinical Pharmacology, Therapy, and Toxicology
|July 1, 1982
PubMed

Insights

Triamcinolone acetonide (TA) treatment temporarily suppressed the ability of human immune cells (polymorphonuclear leukocytes) to engulf bacteria, with effects normalizing within two weeks.

Area of Science:

  • Immunology
  • Pharmacology

Background:

  • Phagocytosis is a critical immune process mediated by polymorphonuclear leukocytes (PMN).
  • Asthma and bronchitis patients often receive corticosteroid treatments like triamcinolone acetonide (TA).

Purpose of the Study:

  • To investigate the impact of triamcinolone acetonide (TA) on the phagocytic capacity of human PMN in patients with respiratory conditions.
  • To quantify the effect of TA on Staphylococcus aureus engulfment by PMN.

Main Methods:

  • Isolation of PMN from 50 asthmatic and bronchitic patients undergoing TA treatment.
  • Utilizing 3H-thymidine-labeled Staphylococcus aureus Cowen-3 to assess bacterial phagocytosis by isolated PMN.
  • Monitoring phagocytic activity at various time points post-TA treatment.

Main Results:

  • Phagocytosis of Staphylococcus aureus by PMN was significantly inhibited in patients treated with TA.
  • The strongest suppression of phagocytic activity was observed on the third day after TA administration.
  • Phagocytic activity gradually recovered, returning to normal levels by day 14.

Conclusions:

  • Triamcinolone acetonide (TA) demonstrates a transient inhibitory effect on PMN phagocytosis in patients with asthma and bronchitis.
  • The observed immunosuppression is temporary, with immune function recovering within two weeks.
  • These findings highlight the need to consider the impact of corticosteroid therapy on innate immune responses.

Related Concept Videos